©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 28, 2012; 18(20): 2533-2539
Published online May 28, 2012. doi: 10.3748/wjg.v18.i20.2533
Published online May 28, 2012. doi: 10.3748/wjg.v18.i20.2533
Table 3 Treatment modalities for intrahepatic tumor and/or metastatic lung nodule(s)
| Treatment modalities | n (%) |
| Single treatment modality in treated patients (n = 19) | |
| Hepatectomy | 4 (21.1) |
| Pulmonary metastasectomy | 0 (0) |
| Transcatheter arterial chemoembolization | 6 (31.6) |
| Radiotherapy | 5 (26.3) |
| Oral sorafenib | 4 (21.1) |
| Combined treatment modalities in treated patients (n = 35) | |
| Hepatectomy + pulmonary metastasectomy | 3 (8.6) |
| Hepatectomy + pulmonary metastasectomy + oral sorafenib | 1 (2.9) |
| Hepatectomy + transcatheter arterial chemoembolization + radiotherapy | 6 (17.1) |
| Hepatectomy + radiotherapy | 9 (25.7) |
| Hepatectomy + transcatheter arterial chemoembolization + radiotherapy + oral sorafenib | 2 (5.7) |
| Hepatectomy + radiotherapy + oral sorafenib | 2 (5.7) |
| Transcatheter arterial chemoembolization + radiotherapy | 6 (17.1) |
| Transcatheter arterial chemoembolization + radiotherapy + oral sorafenib | 3 (8.6) |
| Transcatheter arterial chemoembolization + oral sorafenib | 1 (2.9) |
| Radiotherapy + oral sorafenib | 2 (5.7) |
- Citation: Yang T, Lu JH, Lin C, Shi S, Chen TH, Zhao RH, Wang Y, Wu MC. Concomitant lung metastasis in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(20): 2533-2539
- URL: https://www.wjgnet.com/1007-9327/full/v18/i20/2533.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i20.2533